article thumbnail

Madrigal, FDA approval in hand, outlines plan to sell MASH drug

Bio Pharma Dive

The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.

article thumbnail

FDA approves AstraZeneca, Daiichi drug in breast cancer first

Bio Pharma Dive

Enhertu is the first targeted treatment cleared for breast cancers that are ‘HER2 low,’ a new classification that could change how doctors treat the disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Bio Pharma Dive

But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness. Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations.

Sales 340
article thumbnail

FDA turns down Outlook's ophthalmic version of Roche's Avastin over manufacturing, data shortfalls

Fierce Pharma

Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases.

article thumbnail

Konvomep Gets FDA Approval as a New Oral Liquid Formulation Option of Omeprazole

XTalks

Doctors may prescribe a proton pump inhibitor (PPI), such as omeprazole, which blocks acid-producing cells to protect the gastric ulcer from acid while it heals naturally. If the suspected cause of a gastric ulcer is due to an NSAID, another type of pain reliever may be recommended, such as paracetamol.

article thumbnail

FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivity

Pharmaceutical Technology

In addition, for doctors who do use Lucentis, there will be added pressure from payers to switch to Cimerli with its direct interchangeability with Lucentis approved. The post FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivity appeared first on Pharmaceutical Technology.

article thumbnail

Opinion: Monkeypox patients should not be left to suffer when an FDA-approved drug could help

STAT News

It was the weekend: his doctor wasn’t available, an emergency department provider told him he might have anal cancer, and an urgent care provider sent him home with Tylenol and no diagnosis. Andy couldn’t sleep more than a couple fitful hours a night because it felt like a hot fork was stabbing him in the butt.